8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals

1. A compound which is the monohydrochloride or dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in crystalline anhydrous form.

2. A compound which is the monohydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine having a melting point of 260° C. to 270° C.

3. A compound which is the monohydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and wherein an x-ray powder diagram of the monohydrochloride comprises the characteristic values 2θ=8.51°, 9.83°, 13.01°, 17.07°, 20.00°, 20.60°, 22.33°, 22.61°, 24.91°, and 25.43° with intensities of at least about 10%.

4. A compound which is the dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine having a melting point of 200° C. to 210° C.

5. A compound which is the dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and wherein an x-ray powder diagram of the dihydrochloride comprises the characteristic values 2θ=7.86°, 10.04°, 11.53°, 12.20°, 15.77°, 18.50°, 21.64°, 26.79°, 29.48°, and 30.16° with intensities of at least about 18%.

6. A pharmaceutical composition comprising an excipient and a compound which is the monohydrochloride or dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in crystalline anhydrous form.

7. A pharmaceutical composition comprising an excipient and a compound which is the monohydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine having a melting point of 260° C. to 270° C.

8. A pharmaceutical composition comprising an excipient and a compound which is the monohydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and wherein an x-ray powder diagram of the monohydrochloride comprises the characteristic values 2θ=8.51°, 9.83°, 13.01°, 17.07°, 20.00°, 20.60°, 22.33°, 22.61°, 24.91°, and 25.43° with intensities of at least about 10%.

9. A pharmaceutical composition comprising an excipient and a compound which is the dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine having a melting point of 200° C. to 210° C.

10. A pharmaceutical composition comprising an excipient and a compound which is the dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and wherein an x-ray powder diagram of the dihydrochloride comprises the characteristic values 2θ=7.86°, 10.04°, 11.53°, 12.20°, 15.77°, 18.50°, 21.64°, 26.79°, 29.48°, and 30.16° with intensities of at least about 18%.

11. A method for treating Type II diabetes mellitus or obesity in a mammal comprising administering to a mammal in need thereof a compound which is the monohydrochloride or dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in crystalline anhydrous form.

12. A method for treating Type II diabetes mellitus or obesity in a mammal comprising administering to a mammal in need thereof a compound which is the monohydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine having a melting point of 260° C. to 270° C.

13. A method for treating Type II diabetes mellitus or obesity in a mammal comprising administering to a mammal in need thereof a compound which is the monohydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and wherein an x-ray powder diagram of the monohydrochloride comprises the characteristic values 2θ=8.51°, 9.83°, 13.01°, 17.07°, 20.00°, 20.60°, 22.33°, 22.61°, 24.91°, and 25.43° with intensities of at least about 10%.

14. A method for treating Type II diabetes mellitus or obesity in a mammal comprising administering to a mammal in need thereof a compound which is the dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine having a melting point of 200° C. to 210° C.

15. A method for treating Type II diabetes mellitus or obesity in a mammal comprising administering to a mammal in need thereof a compound which is the dihydrochloride salt of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, and wherein an x-ray powder diagram of the dihydrochloride comprises the characteristic values 2θ=7.86°, 10.04°, 11.53°, 12.20°, 15.77°, 18.50°, 21.64°, 26.79°, 29.48°, and 30.16° with intensities of at least about 18%.

16. The compound of claim 2 , wherein the (R) configuration compound is isolated from the corresponding (S) configuration compound.

17. The compound of claim 3 , wherein the (R) configuration compound is isolated from the corresponding (S) configuration compound.

18. The compound of claim 4 , wherein the (R) configuration compound is isolated from the corresponding (S) configuration compound.

19. The compound of claim 5 , wherein the (R) configuration compound is isolated from the corresponding (S) configuration compound.

20. The monohydrochloride compound of claim 2 , wherein an x-ray powder diagram of the monohydrochloride compound comprises the characteristic values 2θ=8.51°, 9.83°, 13.01°, 17.07°, 20.00°, 20.60°, 22.33°, 22.61°, 24.91°, and 25.43° with intensities of at least about 10%.

21. The dihydrochloride compound of claim 4 , wherein an x-ray powder diagram of the dihydrochloride compound comprises the characteristic values 2θ=7.86°, 10.04°, 11.53°, 12.20°, 15.77°, 18.50°, 21.64°, 26.79°, 29.48°, and 30.16° with intensities of at least about 18%.